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Maija Puhka8, Johannes R. Hov1,2,9, Susanne Dam Nielsen5, Reidun Øvstebø2,3,7,12 & 
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HIV and type 2 diabetes (T2D) are both associated with gut microbiota alterations, low‑grade 
endotoxemia and increased cardiovascular risk. We investigated the potential role of plasma 
extracellular vesicles (EVs) in relation to these processes. Plasma EVs were isolated by size exclusion 
chromatography in fasting individuals with HIV and T2D (n = 16), T2D only (n = 14), HIV only (n = 20) 
or healthy controls (n = 19), and characterized by transmission electron microscopy, western blot, 
nanoparticle tracking analysis and quantitative proteomics. The findings were compared to gut 
microbiota alterations, lipopolysaccharide levels and cardiovascular risk profile. Individuals with 
concomitant HIV and T2D had higher plasma EV concentration, which correlated closely with plasma 
lipopolysaccharides, triglycerides and Framingham score, but not with gut microbiota alterations. 
Proteomic analyses identified 558 human proteins, largely related to cardiometabolic disease genes 
and upstream regulation of inflammatory pathways, including IL‑6 and IL‑1β, as well as 30 bacterial 
proteins, mostly from lipopolysaccharide‑producing Proteobacteria. Our study supports that EVs are 
related to microbial translocation processes in individuals with HIV and T2D. Their proteomic content 
suggests a contributing role in low‑grade inflammation and cardiovascular risk development. The 
present approach for exploring gut‑host crosstalk can potentially identify novel diagnostic biomarkers 
and therapeutic targets.
Human immunodeficiency virus (HIV) and type 2 diabetes (T2D) are chronic diseases associated with low-
grade inflammation and increased risk of cardiovascular disease (CVD)1,2. An increasing body of evidence has 
linked functional alterations in the gut microbiota to several chronic diseases, including  HIV3–5,  T2D6,7 and 
increased cardiovascular  risk8,9. However, a complete understanding of the microbe-host crosstalk mediating 
this risk is lacking.
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A possible factor in this process is the translocation of microbial products, such as lipopolysaccharides (LPS, 
endotoxin) across an impaired gut mucosal membrane to the circulation, also denoted microbial  translocation10 
or endotoxemia. Increased plasma levels of LPS have been linked to cardiovascular risk in  T2D8,11, as well as 
dyslipidemia, platelet activation and endothelial dysfunction in HIV-infected  individuals12,13. While translo-
cated LPS is typically described as single molecules or associated with lipoproteins, LPS can also be released as 
a membrane-associated molecule through extracellular vesicles (EVs)14.
Cell-derived EVs, including bacterial outer membrane vesicles (OMVs), have emerged as important modula-
tors of intercellular communication and host-microbe  crosstalk15–17, including in inflammatory disorders and 
cardiovascular  disease18–20. Along with the increased recognition of the gut microbiota in human  disease21,22, we 
aimed to explore EVs as potential mediators in the crosstalk between microbial products, host inflammation and 
cardiovascular risk. Specifically, we set out to characterize and study the proteomic content of plasma EVs from 
patients with HIV and T2D, and compare EV-related parameters to functional changes in the gut microbiota and 
cardiovascular risk profile. A secondary aim was to investigate whether EVs and their proteomic content may 
present information on microbial translocation processes beyond circulating LPS in these patients.
Results
Characterization of size exclusion chromatography isolates confirmed the presence of 
EVs. The presence, morphology and purity of EV isolates were evaluated by transmission electron micros-
copy (TEM), displaying typical cup-shaped bilayer EV-like structures in pooled SEC isolates of the four study 
groups. Other molecular structures were also apparent in the preparations, which suggested the co-presence of 
plasma lipoprotein particles, identified by their non-collapsed very round shape and staining characteristics, and 
some other matrix, such as protein aggregates (Fig. 1).
Western blot analysis confirmed the presence of the EV-associated markers CD9 and Hsc70/Hsp70 in the EV 
preparation of all four plasma pools as well as in the SW480 cell lysate (positive control) (Fig. 2). As expected, 
the endoplasmic reticulum marker Calnexin (non-EV-associated) was detected in the SW480 cell lysate, but 
not in the EV isolates.
HIV‑infected individuals with T2D have higher concentration of EVs. Individual EV isolates were 
characterized by nanoparticle tracking analysis (NTA). HIV-infected individuals with T2D had significantly 
higher particle concentration (hereafter referred to as ‘EV concentration’) than controls, p = 0.002 (Fig. 3a). We 
also observed significantly smaller mode (peak) particle size in type 2 diabetes, and numerically smaller in 
HIV + T2D, possibly due to higher concentration of small-size exosomes (Fig. 3c). However, there were no sig-
nificant group differences for mean particle size (Fig. 3b).
EV concentration correlates with plasma LPS, lipoprotein content and Framingham score, but 
not with gut microbiota alterations. In the overall study cohort, plasma EV concentration correlated 
with plasma levels of LPS (Fig. 4a) (Table 1), which seemed to be mainly driven by HIV infection (Spearman’s ρ 
0.533, p = 0.001). From the present cohort, Hoel et al. previously reported reduced microbial alpha diversity in 
Figure 1.  Transmission electron microscopy of SEC-isolated plasma EV pools from individuals with 
HIV + T2D (a, b), T2D (c, d), HIV (e, f) and controls (g, h). The top four close-up images have scale bars 
of 200 nm, whereas the bottom four show wide-field images of the same areas with scale bars of 500 nm. 
Different structures are highlighted with arrows, resembling EVs (red), lipoprotein particles (white) and protein 
aggregates or other matrix from plasma (dark grey).
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Figure 2.  Western blot detection of CD9, Hsc70/Hsp70 and Calnexin in plasma pool EVs. As a positive control, 
lysate from the colorectal cancer cell line SW480 was used. Full-length blots are presented in Supplementary 
Fig. 3 (Supplementary Information).
Figure 3.  Characterization of EV isolates by NTA. Data are shown as median values with interquartile range (a) 
or mean values with SD (b, c). All groups were compared using either Mann–Whitney U test (a) or parametric 
t-test (b, c). *p < 0.05, **p < 0.005.
Figure 4.  Grouped scatterplots of plasma LPS (a), plasma triglycerides (b) and Framingham risk score 
(CVD10) (c) by particle concentration as listed in Table 1.
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HIV-infected individuals with T2D compared with  controls23. In our study, plasma EV concentration did not 
correlate with microbial alpha diversity (Table 1), nor with compositional gut microbiota alterations, such as 
increased abundance of Enterobacteriales, as previously reported from this  cohort23. 
Plasma lipoprotein particles are transport vehicles for lipids, including triglycerides and cholesterol. Due 
to their similar size, some lipoprotein particles could be co-isolated with EVs by SEC. We therefore wanted to 
explore the associations between particle concentration, LPS and lipids, including triglycerides and cholesterol 
(total, HDL-bound and LDL-bound). Accordingly, EV concentration strongly correlated with plasma triglyc-
erides and negatively with plasma HDL-bound cholesterol (Table 1). We also found that plasma LPS correlated 
strongly with triglycerides, but also moderately with total cholesterol and negatively with HDL-bound choles-
terol (Table 1). There were no associations found for total cholesterol or LDL-bound cholesterol regarding EV 
concentration. To address the approximate lipoprotein content of our EV isolates, we quantified levels of the 
commonly abundant Apolipoprotein A1 (ApoA1), a major constituent of HDL particles, and Apolipoprotein 
B (ApoB), a major constituent of chylomicrons and LDL particles, in EV fractions from pooled plasma of the 
four study groups. The fractions contained 20–40 ng/mL ApoA1 and 3500–5500 ng/mL ApoB (Supplementary 
Fig. 1 and Supplementary Methods).
We next aimed to explore EV concentrations and LPS as potential biomarkers related to cardiovascular risk 
profile as assessed by Framingham risk score. Whereas EV levels correlated significantly with increased Framing-
ham score (Fig. 4), plasma LPS did not. Despite the higher proportion of smokers in the HIV + T2D group 
(50–100% higher than the other groups), we did not find any difference in EV concentration when comparing 
smokers (n = 55) to non-smokers (n = 14) in the total study cohort (p = 0.7).
Proteomic analyses related to cardiometabolic disease genes and activated inflammation in 
EV fractions from study participants. To further elucidate on the possible link between EVs, microbial 
translocation and cardiovascular risk, we characterized the protein content of EVs using quantitative, label-free 
mass spectrometry (MS)-based proteomics. In total, we identified 558 human proteins in the EV isolates (Sup-
plementary File 1). From the identified proteins, 60 matched to the Vesiclepedia Top 100 EV protein database 
(Fig. 5a), including the tetraspanins CD9, CD81 as well as Flotillin-1, often reported as EV-associated markers. 
In addition, several common high-abundant plasma proteins were among the top 50 identified proteins accord-
ing to MS-intensity values, such as apolipoproteins, albumin, fibrinogen, immunoglobulins and cytoskeleton-
associated proteins (Supplementary File 1). However, of the top 50 most abundant proteins, we also detected 
CD5 antigen-like (CD5L) and galectin-3-binding protein (LGALS3BP), previously suggested as suitable markers 
of plasma-derived EVs in proteomic identification by  MS24,25.
Gene ontology analyses of the whole dataset showed that the top cellular compartments of matched protein 
identifications largely related to extracellular vesicles and extracellular region (Fig. 5b). Metabolic disease and 
cardiovascular disease were identified as the top disease classes (Fig. 5b). Furthermore, database search against 
bacterial proteins resulted in 30 bacterial protein hits originating from 27 different species (counting the first 
detected species listed by MaxQuant), of which 19 belonged to the bacterial phylum Proteobacteria (Supple-
mentary file 2).
To compare the proteomic fingerprint of EVs in the different study groups, we first evaluated the samples 
by principal component analysis (PCA) (Fig. 5c). Samples from the HIV + T2D as well as the HIV only group, 
were similarly distributed across the principal components, whereas samples from the T2D only group and the 
controls seemed to cluster separately. EV isolates from plasma pools distributed representatively according to 
the groups, except for the T2D pool, positioned slightly outside the clustering of the individual samples.
Table 1.  Spearman correlation analyses.
Spearman’s ρ p
EV concentration (particles/mL) vs
Shannon diversity index − 0.08 0.50
Observed species − 0.01 0.94
Enterobacteriales − 0.07 0.58
Plasma LPS 0.54 < 0.001
Plasma triglycerides 0.78 < 0.001
Plasma cholesterol 0.06 0.60
HDL-cholesterol − 0.44 < 0.001
LDL-cholesterol − 0.06 0.61
Framingham score CVD10 0.34 0.007
Plasma LPS vs
Plasma triglycerides 0.66 < 0.001
Plasma cholesterol 0.30 0.011
HDL-cholesterol − 0.31 0.008
LDL-cholesterol 0.09 0.47
Framingham score CVD10 0.17 0.16
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We then compared proteins in the different patient groups against controls (t-test, p < 0.05) which showed 50, 
111 and 26 differentially abundant proteins in HIV + T2D, T2D and HIV groups compared to controls, respec-
tively (Supplementary File 11. Pathway analysis showed that in HIV-infected individuals with T2D, proteins 
were largely related to upstream regulators of inflammatory pathways, including Interleukin-6 (IL-6), as well as 
inflammasome activation by IL-1β (Fig. 5d). Alterations were also apparent in upstream regulation of LPS in 
all group comparisons, particularly in T2D compared with controls. In addition, TGF-β, involved in immune 
regulation, was identified as an upstream regulator, particularly in T2D irrespective of HIV status. Finally, the 
abundance of the identified plasma EV markers CD5L and LGALS3BP were higher in HIV + T2D than controls, 
and CD5L higher in T2D than controls (Supplementary file 1).
In vitro pro‑inflammatory effect of plasma EVs from patients with HIV and type 2 diabe‑
tes. To investigate a possible contribution of circulating EVs to low-grade inflammation in patients with HIV 
and type 2 diabetes, we stimulated human primary monocytes with EVs from patients and controls of the pre-
sent cohort. Patient EVs seemed to trigger a slightly higher pro-inflammatory response in the monocytes than 
EVs from controls, as measured by release of IL-1β and IL-6 to the supernatant after three hours of incubation 
(Supplementary Fig. 2a and Supplementary Methods).
While we hypothesize that the number of circulating bacterial EVs in patients with HIV and type 2 diabetes 
could be key contributors to this pro-inflammatory effect, and presumably higher in these individuals than in 
healthy ones, the exact ratio of bacterial to host EVs remains unknown. We therefore also stimulated monocytes 
with bacterial OMVs from Neisseria meningitidis in different concentrations, finding a dose-dependent response 
of IL-1β and IL-6 in the monocytes (Supplementary Fig. 2b).
Discussion
In the present study, we aimed to explore the potential role of plasma EVs as mediators of microbial transloca-
tion and drivers of cardiometabolic risk. We observed higher EV concentrations in patients with combined HIV 
and T2D compared with controls, and EV levels correlated closely with plasma levels of LPS and triglycerides, 
but not with gut microbiota alterations. Furthermore, EV concentration but not plasma LPS was associated 
with an increased 10-year risk of cardiovascular disease. Lastly, the proteomic content of plasma EVs isolated 
Figure 5.  (a) Venn diagram showing identified proteins (Swissprot, human) compared with the top 100 
identified EV-associated proteins from Vesiclepedia database. (b) Selected gene ontology analyses of the 
identified proteins sorted by gene count. (c) Principal component analysis of all individual samples analyzed 
by MS, HIV + T2D in green (n = 16), T2D only in purple (n = 9), HIV only in blue (n = 14) and controls in 
red (n = 7). Open squares are patient group pools. (d) Ingenuity Pathway Analysis showing the top upstream 
regulators for the differentially abundant proteins in the sample groups (Supplementary File 1).
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from HIV-infected individuals with T2D, was at top related to metabolic and cardiovascular disease genes and 
upstream regulation of inflammatory pathways, including IL-6 and inflammasome activation (IL-1β). Proteins 
of bacterial origin were also identified, mostly from lipopolysaccharide-producing Proteobacteria.
Isolation of EVs from plasma samples is challenging due to the large amount of abundant proteins, including 
lipoproteins. In recent years, size exclusion chromatography (SEC) has been utilized as a fast and gentle stand-
alone method for isolation of biologically active EVs from human  plasma24,26,27. While SEC does not completely 
separate plasma EVs from lipoprotein particles, several combined approaches have been suggested to further 
improve the purity of EV-enriched fractions from plasma, including the combination of liquid chromatography 
with density gradient  separation28–30. However, the approaches seem to be at the expense of EV yield, and often 
require larger sample volume than what is available from clinical material. Furthermore, there are emerging 
results of interactions of EVs with other components of the plasma, including proteins and lipoproteins, and their 
possible significance to both biological functions and biomarker  discovery31,32. In our study, we have taken into 
account that the EV isolates contain a fraction of similarly sized particles to EVs, such as lipoprotein particles, 
which might explain some of our findings.
Increased plasma EV levels have been reported in several disease states, including  HIV33–35 and  T2D36,37. In 
our study, we observed significantly higher EV concentrations in individuals with HIV and T2D than controls, 
and numerically higher in HIV only and T2D only compared to controls. The non-significant differences between 
these disease groups might be due to the relatively low sample size in our study. Of note, the proportion of smok-
ers in our study was around 50–100% higher in the HIV + T2D group compared to other groups (Table 2), hence 
this might influence our findings. A possible link between smoking and HIV pathogenesis has also previously 
been  described38,39. Nevertheless, we did not find any differences in EV concentration regarding smoking. Hence, 
our results support a potentially additive effect of HIV infection and T2D on EV concentration in the circulation.
We observed an inter-correlation between EV concentration and plasma levels of both LPS and triglycerides, 
in line with others reporting on associations between LPS and  triglycerides12. Thus, the question arises whether 
circulating LPS is translocated in complex with triglyceride-rich lipoprotein particles, such as chylomicrons, or 
Table 2.  Characteristics of the study participants. p value refers to one-way ANOVA for continuous data and 
Chi-Square or Fisher’s exact test for categorical data. Results are given as % or mean and 95% CI. PI Protease 
inhibitor, NNRTI Non-nucleoside reverse-transcriptase inhibitor, ACE Angiotensin-converting enzyme, ATII 
Angiotensin II, MSM Men who have sex with men, IDU Intravenous drug use, ART Antiretroviral therapy, 
LDL Low-density lipoprotein, HDL High-density lipoprotein, BMI Body mass index, BP Blood pressure. b,c,d 
refers to t-test; bp < 0.05 versus T2D, cp < 0.05 versus HIV, dp < 0.05 versus HIV + T2D.
HIV + T2D T2D HIV Controls p
N 16 14 21 20
Age (years) 57 (53–62) 58 (54–61) 55 (51–58) 58 (55–61) 0.55
Gender (% male) 88 71 95 90 0.25
Smoker (%) 31 14 14 20 0.64
Use of medication (%)
 PI 38 – 67 – 0.10
 NNRTI 63 – 29 – 0.052
 Statins 69 71 5 15  < 0.001
 Betablockers 25 7 5 0 0.051
 ACE inhibitor/ATII Antagonist 56 36 10 25 0.019
 Oral antidiabetics 81 71 – – 0.68
 Insulin 25 14 – – 0.66
Physical activity (< 1/1–2/ ≥ 3 times/week) 44/31/19 29/21/29 33/29/33 20/35/45 0.47
HIV transmission (MSM, heterosexual, IDU) (%) 69/6/13 – 71/19/0 – 0.38
Time on stable ART (months) 132 (91–174) – 122 (82–161) – 0.670
HIV RNA (copies/mL) 29 (14–43) – 30 (18–42) – 0.62
CD4 count (cells/µL) 630 (488–773) 1088 (901–1274)c,d 580 (460–699) 870 (704–1036)b,c,d  < 0.001
LPS (EU/mL) 65 (54–76) 56 (41–72) 62 (52–72) 60 (43–77) 0.56
Total cholesterol (mmol/L) 4.6 (4.2–4.9) 4.4 (3.8–4.9) 5.5 (5.1–6.0)b,d 5.3 (4.9–5.8)b,d 0.001
HDL cholesterol (mmol/L) 1.2 (1.0–1.4) 1.3 (1.1–1.5) 1.4 (1.2–1.6) 1.7 (1.4–1.9)b,d 0.009
LDL cholesterol (mmol/L) 2.4 (2.0–2.9) 2.4 (1.9–3.0) 3.5 (2.0–3.9)b,d 3.4 (3.1–3.7)b,d  < 0.001
Triglycerides (mmol/L) 2.7 (1.8–3.5) 2.2 (1.5–2.9) 1.9 (1.3–2.5) 1.3 (1.0–1.6)b,d 0.008
Fasting BG (mmol/L) 8.0 (6.6–9.4) 8.8 (7.5–10.1) 5.3 (5.1–5.5)b,d 5.2 (5.0–5.5)b,d  < 0.001
HbA1c (mmol/mol) 48 (43–53) 57 (50–63) 35 (33–37)b,d 37 (36–38)b,d  < 0.001
Systolic BP (mmHg) 129 (122–136) 137 (131–144) 129 (122–136) 136 (130–142) 0.13
Diastolic BP (mmHg) 82 (77–87) 87 (81–92) 80 (76–84) 84 (80–87) 0.23
BMI (kg/m2) 27 (25–29) 28 (26–30) 25 (23–27) 25 (24–26)b 0.045
Framingham risk score (CVD10) 26 (19–33) 24 (17–31) 15 (11–20)b,d 17 (13–21)b,d 0.011
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with bacterially derived EVs, or even as soluble molecules. Of note, 90% of plasma LPS has been shown to be 
lipoprotein-bound, with highest affinity for HDL, medium affinity for low-density lipoprotein (LDL), and low 
affinity for very LDL (VLDL), due to the differential phospholipid  composition40,41. While EVs separated from 
healthy plasma incubated with bacterial OMVs seem to co-localize with the majority of LPS, but not with HDL 
particles, following SEC fractionation (data not shown), the exact translocation route of vesicle-associated LPS 
remains unclear. Nevertheless, our findings suggest that there is a potential interplay between EVs and lipoprotein 
particles involved in the process of microbial translocation.
We have recently reported that HIV-associated gut microbiota alterations, including higher relative abun-
dance of gram-negative LPS-producing Gammaproteobacteria, are closely associated with abdominal obesity and 
excess metabolic  risk42. Although individuals with combined HIV and T2D in the present cohort had increased 
abundance of gram-negative  Enterobacteriales23, we found no correlation between compositional gut micro-
biota alterations and circulating EVs. While the observed gut microbiota alterations does not seem to drive the 
association of increased EV concentration or plasma levels of LPS, alterations in other taxa of LPS-producers, 
in particular mucosa adherent microbes not captured in regular stool samples, could still lead to increased 
levels of LPS-positive OMVs in the circulation. While gut microbe-derived EVs have been shown to translocate 
across the intestinal barrier and distribute into the insulin-responsive tissues and induce insulin resistance and 
glucose  intolerance43, we detected several bacterial proteins in the EV isolates, of which approximately 70% of 
the identified species origins belonged to the bacterial phylum Proteobacteria, which are LPS-producing gram-
negative bacteria. Although the taxonomic classification of bacterial proteins by mass spectrometry in our study 
was suboptimal due to the low numbers of identified peptides, the findings might be supportive of bacterial 
translocation beyond LPS in the circulation.
In our study, EV concentration, but not LPS, correlated with increased 10-year Framingham risk score for 
cardiovascular disease. This correlation could partly be affected by increased plasma triglycerides, although tri-
glycerides is not involved in the Framingham score, in contrast to cholesterol, which did not correlate with EV 
concentration. To further explore the role of EVs as potential drivers of cardiovascular risk beyond lipoproteins 
using proteomics, we identified 50, 111 and 26 differentially abundant proteins in HIV + T2D, T2D and HIV 
groups compared to controls, respectively. Importantly, we identified proteins involved in upstream regulation 
of inflammatory pathways, most prominently the upstream regulator of IL-6. Moreover, our in vitro experiments 
support a possible contribution of plasma EVs to the low-grade inflammation observed in the patient groups, as 
judged by the slightly higher production of IL-1β and IL-6 in the EV-exposed monocytes. Of note, the presence 
of circulating LPS-positive bacterial EVs that are able to induce immune activation has been reported in plasma 
in patients diagnosed with IBD, HIV and cancer therapy-induced intestinal  mucositis14. Hence, we speculate that 
translocated bacterial EVs from the gut to the circulation could contribute to the observed low-grade inflamma-
tion in our study, supported by a dose-dependent pro-inflammatory response in monocytes treated with OMVs 
from Neisseria Meningitidis. Another possible contribution to chronic inflammation may be EVs released from 
latently HIV-infected cells that transfer viral proteins and pro-inflammatory molecules to circulating immune 
cells, even in the presence of stable ART 44. This could also be the case for the HIV-infected individuals in our 
study; however this could not explain the presence of pro-inflammatory EVs in individuals with T2D.
Increased levels of pro-inflammatory IL-6 have in several publications been a marker for cardiovascular events 
in PLWH and in the general  population45–47. Moreover, upstream regulation of inflammasome activation and 
IL-1β could be relevant as we recently reported IL-1 activation as a predictor of first-time myocardial infarction 
in  PLWH48. Of note, IL-6 and IL-1 are both available for pharmaceutical intervention, and in the large CAN-
TOS trial, IL-1 inhibition decreased the risk of recurrent myocardial  infarction49. The observed alterations in 
upstream regulation of LPS in all patient groups, particularly in T2D, could possibly be due to the high number 
of identified proteins in this group.
Furthermore, we observed higher levels of novel plasma EV markers CD5L and LGALS3BP in individuals 
with HIV and T2D than controls. CD5L and LGALS3BP are secretory proteins belonging to the superfamily of 
scavenger receptor cysteine-rich (SRCR) proteins, mostly expressed by macrophages in lymphoid and inflamed 
 tissues50,51. During the last decade, CD5L has gained increasing importance as a critical player in pattern-rec-
ognition of microbial components, as well as in controlling key mechanisms in inflammatory responses related 
to infection, atherosclerosis and  cancer51. Moreover, high LGALS3BP levels has been associated with long-term 
mortality in in coronary artery  disease52.
A limitation of the present study is the cross-sectional design and the relatively small number of study partici-
pants, with several comorbidities and treatment therapies, excluding the possibility to draw causal conclusions. 
Moreover, the available plasma volume in many clinical studies is insufficient to efficiently separate EVs from 
abundant plasma proteins, potentially obscuring less abundant EV-associated proteins. This also applies to the 
present study, although the proteomics analyses suggest that EV content could be involved in central inflamma-
tory pathways and mediate cardiovascular risk beyond that of lipoproteins. The obvious strengths of the present 
study include the possibility to compare patient groups with different chronic diseases, and to compare EV-related 
measures with a wide range of clinical and circulating markers as well as microbiota profiles.
In conclusion, our exploratory results suggest a potential interplay between EVs and lipoprotein particles 
involved in the process of microbial translocation in individuals with HIV and T2D. The proteomic content sug-
gests a potential contributing role of EVs in chronic inflammation and cardiovascular risk development. However, 
future studies of plasma EVs from clinical cohorts will depend on larger sample sizes and improved innovative 
methodology to separate similarly sized particles in low-volume clinical samples, to confidently increase our 
understanding of circulating EVs in the process of microbial translocation and increased cardiometabolic risk.
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Methods
Study participants and baseline characteristics. In the present study, 71 individuals were included 
from a Danish cross-sectional cohort with EDTA plasma and stool samples  available53; 16 individuals with con-
comitant HIV and type 2 diabetes (HIV + T2D), 14 with type 2 diabetes only (T2D), 21 with HIV only (HIV) and 
20 healthy controls. All HIV-infected individuals were included at Department of Infectious Diseases, University 
Hospital of Copenhagen, Rigshospitalet and Hvidovre Hospital. Individuals with T2D only were included from 
Department of Endocrinology, and Center of Inflammation and Metabolism, University Hospital of Copenha-
gen, Rigshospitalet. Healthy controls were included from the hospital staff. The study population characteristics 
are displayed in Table 2. All individuals with HIV were on stable antiretroviral therapy (ART) and virally sup-
pressed, whereas all individuals with T2D were treated with diet and/or oral antidiabetics and/or insulin as 
previously  reported53.
Framingham Risk Score was calculated as previously  described53, using age, gender, weight, height, smoking 
status, diabetes, left ventricular hypertrophy on electrocardiogram, systolic blood pressure, total cholesterol and 
HDL-cholesterol.
Sample collection and processing. Fasting EDTA whole blood was placed immediately on ice and cen-
trifuged at 2500 g for 15 min at 4 °C, within 60 min after collection. Plasma was stored at − 80 °C. At inclusion, 
study participants were instructed to collect stool samples in containers without preservatives and shipped by 
mail to Rigshospitalet, where it was stored at − 80 °C.
Blood biochemistry analyses. Glucose, HbA1c, lipid parameters, CD4 T cell count and HIV RNA were 
measured as routine analyses. Lipopolysaccharide bioactivity was analyzed using the limulus amebocyte lysate 
(LAL) colorimetric assay (Lonza, Walkersville, MD) following the manufacturer’s recommendations and per-
formed under regular assessment of possible contamination of tubes and equipment used for collection, process-
ing and analysis. Pyrogen-free tubes were used throughout, samples were diluted tenfold to avoid interference 
with background color, vortexed and preheated to 68 °C for 10 min prior to analyses to dissolve immune com-
plexes as previously  described54. All samples were analyzed in duplicates.
Gut microbiota analyses. We have previously described gut microbiota analyses in detail from the present 
 cohort23. In brief, the 16 s rRNA gene was amplified by PCR from fecal DNA extracts using universal prim-
ers targeting the V3–V4 region along with TruSeq Ilumina adapters. Pooled and normalized amplicons were 
purified and eluted for sequencing on the Illumina MiSeq platform using 250 base pair paired-end protocol 
at the Norwegian Sequencing Centre (Oslo, Norway). For bioinformatic analyses, paired-end reads were pre-
processed and analyzed using QIIME as previously  described23.
Isolation and characterization of plasma EVs. Size exclusion chromatography. Plasma EVs from 
individual samples were isolated using qEV size exclusion chromatography columns (IZON Science, Oxford, 
UK) according to the manufacturer’s protocol. Briefly, columns were equilibrated with 20 mL of 0.1 µm-filtered 
phosphate buffered saline (PBS) (Gibco, Life Technologies) before 400 µL of plasma was added and 500 µL frac-
tions were collected. Fractions 7–9, containing the majority of EVs, were pooled and concentrated using Amicon 
Ultra-2 10 kDa Centrifugal Filter Devices (Merck Millipore). Similarly, for pooled plasma EV preparations of 
each patient group, a total of 1.4 mL plasma were pooled from 60 to 100 µL plasma per individual (HIV + T2D: 
n = 21, T2D: n = 14, HIV: n = 23, Controls: n = 23) and isolated in three runs on the qEV column. All samples 
were stored at − 80 °C.
Transmission electron microscopy. Electron microscopy samples were prepared essentially as  described55. After 
loading EVs from group pools onto 200 mesh copper grids, the samples were fixed with 2% paraformaldehyde 
in 0.1 M NaPO4 buffer, pH 7.0 (NaPO4). Then, grids were washed with the NaPO4 buffer and deionized water, 
negatively stained with 2% neutral uranyl acetate and embedded in methyl cellulose uranyl acetate mixture 
(1.8/0.4%). All samples were viewed using a TECNAI 12 transmission electron microscope (FEI, Hillsboro, OR, 
USA) operating at 80 kV. Images were taken with a Veleta 2kX2k CCD camera and processed with iTEM soft-
ware (Olympus Soft Imaging Solutions).
Western blot. Twenty µL of EVs from group pools were added 6 µL RIPA 5 × buffer (Thermo Fisher Scientific) 
and 1.25 µL protease inhibitor (cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail 25 × , Roche), sonicated 
for 20 s and lysed on ice for 15 min. Then, 10 µL LDS Sample Buffer (Invitrogen) was added. Hsc70/Hsp70 
and calnexin was analyzed under reducing conditions and received 4 µL Bolt Sample Reducing Agent, whereas 
CD9 was added 4 µL of PBS before all lysates were heated for 10 min at 70 °C. Proteins were separated on Bolt 
4–12% Bis–Tris Plus Gels with Bolt MES SDS Running Buffer (both Invitrogen) and transferred to 0.2 µm PVDF 
Blotting Membranes (Invitrogen). Membranes were blocked with 1% casein (Western Blocking Reagent, Sigma 
Aldrich) in tris-buffered saline with 0.1% Tween 20 (TBS-T) for 1 h at room temperature (RT), then incubated 
with primary mouse monoclonal antibodies (anti-CD9, Invitrogen, 10626D (Ts9), 1:750; anti-CD63, Invitrogen, 
10628D (Ts63), 1:500; anti-Hsc70/Hsp70, Enzo Life Science, ADI-SPA-820, 1:1000; anti-Calnexin, Invitrogen, 
MA5-15389, 1:1000) overnight at 4 °C. The membranes were then washed three times 20 min with TBS-T before 
incubation with horseradish peroxidase-coupled secondary antibody (Mouse TrueBlot Ultra, Rockland Immu-
nochemicals, Pottstown, USA) for one hour at RT. Following triplicate washing with TBS-T, blots were imaged 
using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) and Amersham Imager 600 (GE 
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Healthcare, UK). Original images of full-length membrane blots can be found in Supplementary Information 
(Supplementary Fig. 3).
Nanoparticle tracking analysis. EV isolates were analyzed by nanoparticle tracking analysis as previously 
 described56. Briefly, EVs were diluted in 0.02 µm-filtered PBS (Whatman Anotop™25, GE Healthcare Life Sci-
ence, Buckinghamshire, UK), to reach the measurement range (1.0–9.0 ×  108 particles/mL). Samples were loaded 
into a NanoSight NS500 instrument (Malvern, Amesbury, UK) equipped with a sCMOS camera, using a syringe 
pump and flow speed 20. For each sample, three 60-s videos were captured, typically at camera level 14 and 
detection threshold 3, then analyzed using NTA 3.1 software Build 3.1.54.
Proteomics. 50 µL of EVs were mixed with 30 µL ProteaseMAX™ Surfactant (Promega) in 50 mM NH4HCO3. 
The proteins were reduced, alkylated and digested into peptides with trypsin (Promega) according to the Pro-
teaseMax protocol. The resulting peptides were desalted and concentrated with EvoTips (EvoSep). Each pep-
tide mixture was analyzed by EvoSepOne coupled to QExactive HF (ThermoElectron, Bremen, Germany) with 
15 cm EvoSep column using a 30 samples/day method. The resulting MS raw files were submitted to the Max-
Quant software version 1.6.1.0 for protein identification and label free quantification. Carbamidomethyl (C) 
was set as a fixed modification and acetyl (protein N-term), carbamyl (N-term) and oxidation (M) were set as 
variable modifications. First search peptide tolerance of 20 ppm and main search error 4.5 ppm were applied. 
Trypsin without proline restriction enzyme option was used, allowing two miscleavages. The number of minimal 
unique + razor peptides was set to 1, and the allowed FDR was 0.01 (1%) for peptide and protein identifica-
tion. Label-free quantitation was employed with default settings. The Uniprot databases with ‘human’ entries 
(September 2018) as well as ‘bacteria’ entries (May 2020) were used for the database searches. Perseus software 
version 1.6.1.3 was used for the statistical analysis of the results. Known contaminants as provided by MaxQuant 
and identified in the samples were excluded from further analysis. Proteomic venn diagram was created using 
Funrich tool version 3.1.3 (www. funri ch. org). Gene ontology analyses of identified proteins were performed 
using David functional annotation tool (https:// david. ncifc rf. gov), and group comparisons of proteomic data 
were done using Ingenuity® Pathway Analysis (IPA; QIAGEN inc., https:// www. qiage nbioi nform atics. com).
Statistical analysis. Normally distributed continuous data were analysed using parametric two-sample T-test 
for comparison of two groups or one-way ANOVA for multiple groups. Skewed data were log-transformed and 
analysed by parametric statistics or analysed using non-parametric Mann–Whitney U Test or Kruskal–Wallis 
for comparison between two or more groups, respectively. Categorical data was analysed using Pearson chi-
square test. Fisher’s exact test was used whenever applicable. Correlations were performed by Spearman cor-
relation. Two-tailed p values < 0.05 were considered significant. Statistical analyses were performed using SPSS 
version 26 (SPSS, Inc.; Chicago, IL, USA) and GraphPad Prism 8.3.0 (GraphPad Software, San Diego, CA, USA). 
For proteomic data, group comparisons were performed by two-sample T-tests (p < 0.05) on Log10-transformed 
data using Perseus software version 1.6.1.3, requiring at least 50% valid values in at least one group. Missing 
values were imputed from normal distribution.
Ethical considerations. The study was performed in accordance with the Helsinki declaration, approved 
by the The Regional Committees on Health Research Ethics for Southern Denmark (VEK no. H-4-2012-076 and 
H-19028857) and the Danish data protection agency, as well as the Regional Committees for Medical and Health 
Research Ethics in Norway (REK no. 31412). Written informed consent was obtained from all individuals.
Data availability
The datasets generated and/or analyzed during the present study beyond the supplementary anonymized raw 
data are not publicly available due to Danish and Norwegian legislation about general data protection regulation, 
but data are available from the corresponding author on reasonable request. Written details on experimental 
procedures have been submitted to the EV-TRACK knowledgebase (EV-TRACK ID: EV200050)57.
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